"Longitudinal Analysis of Amylin Levels in Migraine Patients Undergoing an Anti- CGRP/CGRPr Treatment"
Launched by FUNDACIÓN MARQUES DE VALDECILLA · Nov 14, 2024
Trial Information
Current as of August 24, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the role of a substance called amylin in patients with high-frequency episodic migraines and chronic migraines who are starting treatment with anti-CGRP medicines. Researchers believe that understanding amylin levels in these patients could help explain why some people do not respond well to migraine treatments. The trial will measure amylin levels in blood samples before and after six months of treatment and look for links between these levels and how well patients respond to their migraine therapy.
To participate, you must be diagnosed with either high-frequency episodic migraine or chronic migraine and have been prescribed anti-CGRP treatment but not yet started it. Healthy volunteers with no history of migraines or headache issues are also needed. During the study, participants will have their blood drawn to check amylin levels, and they will be monitored over time to see how their treatment affects these levels. This trial aims to provide valuable insights that could improve migraine management in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria for patients:
- • Diagnosed with either: a) High Frequency Episodic Migraine or b) Chronic Migraine
- • Prescribed with anti-CGRP/CGRPr monoclonal antibodies whi have not yet started his/her treatment.
- Inclusion Criteria for healthy volunteers:
- • No history or migraine or any other kind of headache.
- • Daily consumption of any kind of analgesic treatment.
- Exclusion Criteria:
- • Younger than 18 years old
About Fundación Marques De Valdecilla
Fundación Marqués de Valdecilla is a leading clinical research organization based in Spain, dedicated to advancing medical knowledge and improving patient care through innovative research initiatives. With a strong emphasis on collaboration, the foundation conducts a wide range of clinical trials across various therapeutic areas, leveraging state-of-the-art facilities and a multidisciplinary team of experts. Committed to ethical standards and regulatory compliance, Fundación Marqués de Valdecilla aims to translate scientific findings into tangible health solutions, fostering a culture of excellence in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported